Dupilumab Effective for Atopic Dermatitis

Outcomes were significantly improved with dupilumab versus placebo in patients with moderate-to-severe disease uncontrolled by topical therapy.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching and intermittent eczematous rash that, with asthma and allergic rhinitis, makes up the atopic triad. Many cases resolve in early childhood, but disease persists into adulthood in up to 10% of patients. Studies on AD immunopathogenesis show that IL-4 and IL-13 are key mediators of the inflammatory response. The monoclonal antibody dupilumab targets the receptor on cells to which IL-4 and IL-13 bind, inhibiting their action. Dupilumab is efficacious for asthma and chronic sinusitis, and preliminary studies have shown that it is effective for AD, as well. Investigators conducted a multinational, randomized, double-blind, phase IIb, placebo-controlle…

Reviewing Author

Craig A. Elmets, MD

Disclosures

Consultant / Advisory board Astellas Pharmaceuticals

EquityVaxin

Grant / Research support NIH; NIH/NCI; Veteran’s Administration; Ferndale Laboratories; Kyowa Hakko Kirin Pharma, Inc.

Editorial boards Cancer Prevention Research; Photodermatology, Photoimmunology, & Photomedicine; UpToDate; eMedicine; Journal of Dermatological Sciences; JAMA Dermatology

Leadership positions in professional societies American Academy of Dermatology (Vice Chair, Committee on Science and Research); Photomedicine Society (Board of Directors)